title: [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
abstract: OBJECTIVE
  Oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) have emerged as the standard of care in the therapy of advanced-stage colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. We decided to use Ca and Mg for prevention of oxaliplatin-related neurotoxicity with reference to the report of Gamelin et al.
  
  
  METHODS
  The subjects were 14 patients with metastatic colorectal cancer. Oxaliplatin (85 mg/m(2)) was given intravenously as FOLFOX regimen. All 14 patients received infusions of Ca gluconate and Mg sulfate before and after oxaliplatin.
  
  
  RESULTS
  Only 1 patient had grade 3 toxicity (nausea and vomiting). Sensory neuropathy occurred in 8 patients (57.1%). There was no neurotoxicity with functional impairment in this study. Sensory neuropathy hardly occurred before 4 cycles.
  
  
  CONCLUSIONS
  Ca/Mg infusions seem to prevent acute oxaliplatin-induced neurotoxic.
authors: Division of Surgery, Nakadori General Hospital.
authors: Osamu
authors: O
authors: Muto
authors: Hideaki
authors: H
authors: Ando
authors: Takashi
authors: T
authors: Ono
authors: Hiroko
authors: H
authors: Itagaki
authors: Yoshio
authors: Y
authors: Kobayashi
authors: Manabu
authors: M
authors: Onuki
authors: Tatsuru
authors: T
authors: Akashi
authors: Yuichi
authors: Y
authors: Tanaka
authors: Takao
authors: T
authors: Hanaoka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D002118:Calcium / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008274:Magnesium / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000517:prevention & control*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000517:prevention & control
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D008274:Magnesium; D002955:Leucovorin; D002118:Calcium; D005472:Fluorouracil